news & insights

Read about our latest innovations.

  • >
  • Tag: Netherton Syndrome

Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents

Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Read More
Copied!
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Read More
Copied!
Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV – February 14, 2024 – Skinvisible, Inc. (“Skinvisible”) (OTCQB: SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ: QNRX). The trials focus on the innovative formulation “QRX003,” powered by Skinvisible’s Invisicare® proprietary drug delivery technology, to address the challenges […]
Read More
Copied!